Oncology Deal Spree To Continue For AbbVie – Early Cancer Pipeline Outweighs Other Disease R&D

Cancer focused and charging forwards, AbbVie makes 2017 the year its pipeline will expand a little more. Scrip looks at the company’s growing oncology portfolio and what is yet to come and speaks to medical affairs head Bianca Wittig about challenges intertwined with oncology R&D.

Scientist conducting a laboratory experiment in a cancer research facility in the United States, 1951.
AbbVie Builds On Abbott's Cancer R&D History • Source: Shutterstock/Everett Historical

Having spent the majority of this year investing heavily in its oncology pipeline, including an acquisition focused on cell therapy assets, AbbVie Inc. is confident it will make clinical progress in cancer in 2017 – boasting a growing pipeline which includes around 16 compounds in more than 200 active trials.

Following a recent event at the Oslo Cancer Cluster in Norway, of which AbbVie is a pharma partner, Bianca Wittig,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category